Can a Newer MR Contrast Agent Be Used to Monitor Disease Progression in Muscular Dystrophy?
| Autor: | Evan C. Unger |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pathology
medicine.medical_specialty Adolescent Contrast Media Sensitivity and Specificity Muscular Dystrophies Dystrophin Mice Image Processing Computer-Assisted Organometallic Compounds medicine Animals Humans Radiology Nuclear Medicine and imaging In patient Muscular dystrophy Child Muscle Skeletal Dysferlin Fluorocarbons business.industry Disease progression Mr contrast agent Gadofluorine M Membrane Proteins Muscular Dystrophy Animal Image Enhancement medicine.disease Magnetic Resonance Imaging Mr imaging Muscular Dystrophy Duchenne Muscular Dystrophies Limb-Girdle Child Preschool Disease Progression business |
| Zdroj: | Radiology. 250:1-3 |
| ISSN: | 1527-1315 0033-8419 |
| Popis: | Schmidt et al (1) showed that MR imaging by using gadofluorine M, a fluorinated macrocyclic gadolinium-based contrast agent, enabled detection of disease progression in a model of muscular dystrophy in mice, whereas a macromolecular contrast agent did not. MR imaging with contrast agents such as gadofluorine M might ultimately be used in patients with muscular dystrophy to monitor disease progression and to assess the effectiveness of newer therapies currently under development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|